Anonymousabout 3 hours ago
Epigenome editing — a technique that modifies gene expression by altering chemical tags on DNA rather than cutting the double helix — has attracted over $600 million in private investment and is entering its first human clinical trials. While proponents argue it offers a safer, reversible alternative to permanent genome editing, critics warn that the 'safer' label may be premature, pointing to unresolved off-target risks, potential for tumor-suppressor gene silencing, and regulatory frameworks that have yet to catch up with the science.